SCHEMBL24256696

SCHEMBL24256696

CCCc1nc2sc3c(NCc4ccc(OC)c(OC)c4)ncnc3c2c2c1CCC2

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM4 P08173 7/20 0.48
POLB P06746 4/20 0.46
RXFP1 Q9HBX9 2/20 0.46
OPRK1 P41145 1/20 0.46
HTT P42858 3/20 0.45
KDM4E B2RXH2 2/20 0.45
ALDH1A1 P00352 2/20 0.45
MAPT P10636 2/20 0.45
LMNA P02545 1/20 0.45
HPGD P15428 1/20 0.45
TSHR P16473 1/20 0.45
APOBEC3A P31941 1/20 0.45
RECQL P46063 1/20 0.45
BLM P54132 1/20 0.45
APOBEC3G Q9HC16 1/20 0.45
TDP1 Q9NUW8 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
PDE5A O76074 2/20 0.45
TNF P01375 1/20 0.45
NOD1 Q9Y239 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24256356 0.92 NPC1 (0.48) POLBRXFP1OPRK1HTTKDM4E
SCHEMBL24256706 0.92 NPC1 (0.49) POLBRXFP1OPRK1HTTKDM4E
SCHEMBL24256969 0.91 KDM4E (0.46) POLBRXFP1OPRK1HTTKDM4E
SCHEMBL24256703 0.87 POLB (0.47) POLBRXFP1OPRK1HTTKDM4E
SCHEMBL24256354 0.86 POLB (0.52) CHRM4POLBRXFP1OPRK1HTT
SCHEMBL24256615 0.85 KDM4E (0.44) CHRM4POLBRXFP1OPRK1HTT
SCHEMBL24256967 0.84 ALDH1A1 (0.47) CHRM4POLBRXFP1OPRK1HTT
SCHEMBL24256699 0.83 KDM4E (0.49) CHRM4POLBRXFP1OPRK1HTT
SCHEMBL24256689 0.82 ALDH1A1 (0.48) POLBRXFP1OPRK1HTTKDM4E
SCHEMBL24256693 0.80 KDM4E (0.46) POLBRXFP1OPRK1HTTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230365583-A1 FUSED TRICYCLIC PYRIMIDINE-THIENO-PYRIDINE SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 DANA-FARBER CANCER INSTITUTE, INC. 2023-11-16 US disclosed
US-20230365583-A1 FUSED TRICYCLIC PYRIMIDINE-THIENO-PYRIDINE SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 DANA-FARBER CANCER INSTITUTE, INC. 2023-11-16 US disclosed
WO-2022035806-A1 FUSED TRICYCLIC PYRIMIDINE-THIENO-PYRIDINE SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 DANA-FARBER CANCER INSTITUTE, INC. (US) 2022-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230365583-A1 FUSED TRICYCLIC PYRIMIDINE-THIENO-PYRIDINE SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 USP28, USP30, USP8 CHRM4 4873/4885POLB 2123/4885RXFP1 4473/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.